blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2698634

EP2698634 - BIOMARKER FOR BREAST CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.09.2018
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  06.10.2017
FormerGrant of patent is intended
Status updated on  22.05.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
J-Pharma Co., Ltd.
75-1 Onocho
Tsurumi-ku
Yokohama-shi
Kanagawa 230-0046 / JP
[2014/08]
Inventor(s)01 / ENDOU Hitoshi
1-23-7 Yoshinodai
Chuo-Ku
Sagamihara-shi Kanagawa 252-0222 / JP
02 / OKAYASU Isao
1-31-3-219 Takaidohigashi
Suginami-ku
Tokyo 168-0072 / JP
 [2014/08]
Representative(s)Osha BWB
2, rue de la Paix
75002 Paris / FR
[N/P]
Former [2017/45]Osha Liang
2, rue de la Paix
75002 Paris / FR
Former [2014/08]Osha Liang SARL
32, avenue de l'Opéra
75002 Paris / FR
Application number, filing date12770851.913.04.2012
[2017/45]
WO2012JP60114
Priority number, dateJP2011009137815.04.2011         Original published format: JP 2011091378
[2014/08]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012141285
Date:18.10.2012
Language:JA
[2012/42]
Type: A1 Application with search report 
No.:EP2698634
Date:19.02.2014
Language:EN
[2014/08]
Type: B1 Patent specification 
No.:EP2698634
Date:08.11.2017
Language:EN
[2017/45]
Search report(s)International search report - published on:JP18.10.2012
(Supplementary) European search report - dispatched on:EP24.10.2014
ClassificationIPC:G01N33/574, G01N33/48, G01N33/53, C07K16/28
[2014/08]
CPC:
G01N33/57415 (EP,CN,US); G01N33/574 (KR); C07K16/28 (EP,KR,US);
G01N33/48 (KR); G01N33/53 (KR)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/08]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BIOMARKER FÜR BRUSTKREBS[2014/08]
English:BIOMARKER FOR BREAST CANCER[2014/08]
French:BIOMARQUEUR POUR LE CANCER DU SEIN[2014/08]
Entry into regional phase15.11.2013Translation filed 
15.11.2013National basic fee paid 
15.11.2013Search fee paid 
15.11.2013Designation fee(s) paid 
15.11.2013Examination fee paid 
Examination procedure15.11.2013Examination requested  [2014/08]
12.05.2015Amendment by applicant (claims and/or description)
23.05.2017Communication of intention to grant the patent
29.09.2017Fee for grant paid
29.09.2017Fee for publishing/printing paid
29.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.05.2017
Opposition(s)09.08.2018No opposition filed within time limit [2018/42]
Fees paidRenewal fee
28.04.2014Renewal fee patent year 03
27.04.2015Renewal fee patent year 04
29.03.2016Renewal fee patent year 05
21.04.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.04.2012
AL08.11.2017
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
NL08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
MT13.04.2018
BE30.04.2018
[2020/34]
Former [2020/31]HU13.04.2012
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
MK08.11.2017
NL08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
MT13.04.2018
BE30.04.2018
Former [2020/27]HU13.04.2012
AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
PT08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
MT13.04.2018
BE30.04.2018
Former [2020/16]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
TR08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
MT13.04.2018
BE30.04.2018
Former [2020/08]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
MT13.04.2018
BE30.04.2018
Former [2019/19]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
IE13.04.2018
LU13.04.2018
BE30.04.2018
Former [2019/12]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU13.04.2018
BE30.04.2018
Former [2019/08]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
LU13.04.2018
Former [2018/52]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
MC08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SI08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/40]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
NL08.11.2017
PL08.11.2017
RO08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/37]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
NL08.11.2017
PL08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
SM08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/35]AT08.11.2017
CY08.11.2017
CZ08.11.2017
DK08.11.2017
EE08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
NL08.11.2017
RS08.11.2017
SE08.11.2017
SK08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/24]AT08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
LV08.11.2017
NL08.11.2017
RS08.11.2017
SE08.11.2017
BG08.02.2018
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/23]AT08.11.2017
FI08.11.2017
HR08.11.2017
LT08.11.2017
NL08.11.2017
RS08.11.2017
SE08.11.2017
NO08.02.2018
GR09.02.2018
IS08.03.2018
Former [2018/22]FI08.11.2017
LT08.11.2017
NL08.11.2017
NO08.02.2018
Documents cited:Search[XI]EP2146208  (PHARMA CO LTD J [JP]) [X] 1-4 * claim - * * paragraph [0013] - paragraph [0014] * [I] 1-8;
 [XY]EP1111048  (JAPAN SCIENCE & TECH CORP [JP]) [X] 1-4 * claim - * [Y] 1-8;
 [YD]JP2000342270  (JAPAN SCIENCE & TECH CORP) [YD] 1-8 * claim - *
International search[X]JP2011024537  (UNIV KINKI, et al);
 [X]  - SHIN'YA UCHIGASAKI ET AL., "Histopathological and immunohistochemical studies on L-type amino acid transporter 1 (LAT1) expression for breast tumors", JAPANESE JOURNAL OF DIAGNOSTIC PATHOLOGY, (20020731), vol. 19, no. 3, pages 189 - 194, XP008171817
 [Y]  - YUKA SASAKI ET AL., "Bunshi Hyoteki Chiryo to Byori Nyugan to Bunshi Hyoteki Chiryo", PATHOLOGY AND CLINICAL MEDICINE, (20060601), vol. 24, no. 6, pages 625 - 633, XP008171811
 [Y]  - HARUMI NAKAMURA ET AL., "VIII Byori Saiboshin 3 | Nyugan", MODERN MEDICAL LABORATORY, (20100915), vol. 38, no. 10, pages 1003 - 1008, XP008171810
by applicantJP2000157286
 JP2000342270
 JP2001211886
 JP2001046070
 JP2001228146
 JP2001245661
 JPH11511245
    - KANAI, Y. ET AL., J. BIOL. CHEM., (1998), vol. 273, pages 23629 - 23632
    - YANAGIDA 0. ET AL., BIOCHIM. BIOPHYS. ACTA, (2001), vol. 1514, no. 2, pages 291 - 302
    - SEGAWA, H. ET AL., J. BIOL. CHEM., (1999), vol. 274, no. 28, pages 19745 - 19751
    - SAKATA T. ET AL., PATHOL. INT., (2009), vol. 59, pages 7 - 18
    - ODA K. ET AL., CANCER SCI., (2010), vol. 101, pages 173 - 179
    - RAKHA E. A. ET AL., CANCER, (2007), vol. 109, pages 25 - 32
    - LIEDTKE C. ET AL., J. CLIN. ONCOL., (2008), vol. 26, pages 1275 - 1281
    - SASAKI Y. ET AL., BREAST CANCER, (2009), vol. 16, pages 254 - 259
    - IWASE H. ET AL., BREAST CANCER, (2010), vol. 17, pages 118 - 124
    - SINICROPE F. A. ET AL., CANCER RES., (1995), vol. 55, pages 237 - 241
    - Cell engineering Handbook, YODOSHA CO. LTD., (1992), pages 201 - 213
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.